Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped 6% on Monday . The company traded as low as $46.54 and last traded at $46.69. Approximately 660,116 shares traded hands during trading, an increase of 34% from the average daily volume of 493,284 shares. The stock had previously closed at $49.68.

AGIO has been the subject of a number of research reports. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th. ValuEngine cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Piper Jaffray Companies decreased their price target on shares of Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 14th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, February 15th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $95.83.

The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.86 and a current ratio of 6.89. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of -7.85 and a beta of 2.25.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The company had revenue of $30.20 million during the quarter, compared to analysts’ expectations of $22.69 million. Agios Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 48.19%. The firm’s revenue for the quarter was up 243.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.63) EPS. On average, analysts anticipate that Agios Pharmaceuticals Inc will post -6.76 EPS for the current year.

In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 10,000 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $67.01, for a total value of $670,100.00. Following the completion of the transaction, the insider now directly owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $67.71, for a total transaction of $203,130.00. Following the completion of the transaction, the insider now directly owns 29,511 shares of the company’s stock, valued at $1,998,189.81. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,000 shares of company stock valued at $2,765,530. 3.16% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of Agios Pharmaceuticals by 0.3% in the 4th quarter. FMR LLC now owns 8,726,801 shares of the biopharmaceutical company’s stock valued at $402,393,000 after purchasing an additional 27,915 shares in the last quarter. BlackRock Inc. raised its stake in shares of Agios Pharmaceuticals by 0.3% in the 1st quarter. BlackRock Inc. now owns 3,334,365 shares of the biopharmaceutical company’s stock valued at $224,869,000 after purchasing an additional 9,886 shares in the last quarter. BB Biotech AG raised its stake in shares of Agios Pharmaceuticals by 30.9% in the 4th quarter. BB Biotech AG now owns 2,878,134 shares of the biopharmaceutical company’s stock valued at $132,711,000 after purchasing an additional 680,203 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Agios Pharmaceuticals by 31.4% in the 1st quarter. First Trust Advisors LP now owns 1,774,158 shares of the biopharmaceutical company’s stock valued at $119,649,000 after purchasing an additional 423,931 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Agios Pharmaceuticals by 24.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,636,073 shares of the biopharmaceutical company’s stock valued at $110,337,000 after purchasing an additional 320,626 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2019/05/15/agios-pharmaceuticals-agio-shares-down-6.html.

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.

Further Reading: What is the Rule of 72?

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.